CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Treasury Stock	Noncontrolling Interests	Total
Balance, beginning at Dec. 31, 2012	$ 61	$ 493,613	$ (424,105)	$ (260)	$ (2,741)	$ 0	$ 66,568
Balance, beginning (in shares) at Dec. 31, 2012	46,765				(200)
Net loss attributable to noncontrolling interests							0
Net (loss) income attributable to Progenics			(42,572)				(42,572)
Net (loss) income							(42,572)
Other comprehensive income				68			68
Compensation expenses for share-based payment arrangements		3,546					3,546
Acquisition of subsidiary, net of issuance costs	$ 6	11,214					11,220
Acquisition of subsidiary, net of issuance costs (in shares)	4,472
Acquisition of subsidiary escrow shares returned							0
Sale of common stock in public offering, net of underwriting discounts and commissions and offering expenses	$ 12	40,066					40,078
Sale of common stock in public offering, net of underwriting discounts and commissions and offering expenses (in shares)	9,775
Forfeitures of restricted stock	$ 0	0					0
Forfeitures of restricted stock (in shares)	(1)
Exercise of stock options	$ 0	71					71
Exercise of stock options (in shares)	14
Balance, ending at Dec. 31, 2013	$ 79	548,510	(466,677)	(192)	$ (2,741)	0	78,979
Balance, ending (in shares) at Dec. 31, 2013	61,025				(200)
Net loss attributable to noncontrolling interests							0
Net (loss) income attributable to Progenics			4,410				4,410
Net (loss) income							4,410
Other comprehensive income				192			192
Compensation expenses for share-based payment arrangements		3,523					3,523
Acquisition of subsidiary escrow shares returned	$ 0	(82)					(82)
Acquisition of subsidiary escrow shares returned - shares	(19)
Sale of common stock in public offering, net of underwriting discounts and commissions and offering expenses	$ 12	37,447					37,459
Sale of common stock in public offering, net of underwriting discounts and commissions and offering expenses (in shares)	8,750
Exercise of stock options	$ 0	428					428
Exercise of stock options (in shares)	77
Balance, ending at Dec. 31, 2014	$ 91	589,826	(462,267)	0	$ (2,741)	0	124,909
Balance, ending (in shares) at Dec. 31, 2014	69,833				(200)
Net loss attributable to noncontrolling interests						(7)	(7)
Net (loss) income attributable to Progenics			(39,112)				(39,112)
Net (loss) income							(39,119)
Other comprehensive income				(26)			(26)
Compensation expenses for share-based payment arrangements		2,948					2,948
Acquisition of subsidiary escrow shares returned							0
Acquisition of subsidiary						504	504
Purchase of noncontrolling interests						(292)	(292)
Exercise of stock options	$ 0	1,737					$ 1,737
Exercise of stock options (in shares)	313						313
Balance, ending at Dec. 31, 2015	$ 91	$ 594,511	$ (501,379)	$ (26)	$ (2,741)	$ 205	$ 90,661
Balance, ending (in shares) at Dec. 31, 2015	70,146				(200)